A better understanding of the effect of HH/GLI pathway modulators and cancer drugs on the immune response is therefore pivotal and will pave the way towards the next generation of combination therapies involving HH/GLI inhibitors and immunotherapeutic drugs. Here, GLI1 is linked to cancer.